Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMunteanu, M.en
dc.contributor.authorTiniakos, D.en
dc.contributor.authorAnstee, Q.en
dc.contributor.authorCharlotte, F.en
dc.contributor.authorMarchesini, G.en
dc.contributor.authorBugianesi, E.en
dc.contributor.authorTrauner, M.en
dc.contributor.authorRomero Gomez, M.en
dc.contributor.authorOliveira, C.en
dc.contributor.authorDay, C.en
dc.contributor.authorDufour, J.en
dc.contributor.authorBellentani, S.en
dc.contributor.authorNgo, Y.en
dc.contributor.authorTraussnig, S.en
dc.contributor.authorPerazzo, H.en
dc.contributor.authorDeckmyn, O.en
dc.contributor.authorBedossa, P.en
dc.contributor.authorRatziu, V.en
dc.contributor.authorPoynard, T.en
dc.contributor.authorRatziu, V.en
dc.contributor.authoret al.en
dc.identifier.citationAlimentary Pharmacology and Therapeutics, 2016; 44(8):877-889en
dc.description.abstractBackground: Blood tests of liver injury are less well validated in non‐alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. Aims: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. Methods: We pre‐included new NAFLD patients with biopsy and blood tests from a single‐centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary‐ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing. Results: A total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and NAFLD scores (Bonferroni test P < 0.05). Conclusions: In patients with NAFLD, SteatoTest, ActiTest and FibroTest are non‐invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity and fibrosis.en
dc.description.statementofresponsibilityM. Munteanu, D. Tiniakos, Q. Anstee, F. Charlotte, G. Marchesini, E. Bugianesi ... et al.en
dc.publisherWiley Online Libraryen
dc.rights© 2016 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.en
dc.subjectFatty Liveren
dc.titleDiagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological referenceen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidLawlor, D. [0000-0002-6793-2262]en
dc.identifier.orcidBurt, A. [0000-0002-3011-7774]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_118507.pdfPublished version230.06 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.